Prolonged paradoxical response to anti-tuberculous treatment after infliximab

Int J Infect Dis. 2010 Sep:14 Suppl 3:e333-4. doi: 10.1016/j.ijid.2010.03.002. Epub 2010 Jun 25.

Abstract

A 56-year-old woman with ankylosing spondylitis, treated for 3 months with infliximab, developed miliary tuberculosis with mediastinal lymphadenopathies and brain and splenic lesions. After initial improvement under anti-tuberculous therapy, she suffered an unexpectedly prolonged paradoxical worsening with several episodes of lymphadenopathy, including life-threatening ones, over a period of more than 14 months of follow-up. The outcome was favorable as a result of corticosteroid and surgical treatments. This phenomenon reflects a paradoxical reaction precipitated by infliximab withdrawal.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Antibodies, Monoclonal / adverse effects*
  • Antitubercular Agents / adverse effects
  • Antitubercular Agents / therapeutic use
  • Female
  • Humans
  • Infliximab
  • Lymphatic Diseases / etiology
  • Lymphatic Diseases / surgery
  • Lymphatic Diseases / therapy
  • Mediastinal Diseases / etiology
  • Mediastinal Diseases / therapy
  • Middle Aged
  • Opportunistic Infections / etiology
  • Opportunistic Infections / therapy
  • Recurrence
  • Spondylitis, Ankylosing / therapy*
  • Tuberculosis, Miliary / etiology*
  • Tuberculosis, Miliary / therapy*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal
  • Antitubercular Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab